000			nam a22 i 4500
999			_c6598 _d6598
001			6598
003			ES-MaCNC
005			20230614135824.0
008			230124s2022 -uk ||||r|||| 001 0 eng d
020			_a978-1-80220-440-7
040			_aES-MaCNC _cES-MaCNC
245	0	0	_aEU competition law and pharmaceuticals
260			_aCheltenham (UK) _bEdward Elgar _c2022
300			_a307 p. _c24 cm.
336			_2isbdcontent _aTexto (visual)
337			_2isbdmedia _asin mediación
490	0		_aNew Horizons in Competition Law and Economics series
500			_aEditores: Wolf Sauter, Marcel Canoy and Jotte Mulder. Autores: Frederick Abbott, Freek Bruggert, Marcel Canoy, Clara Ceulemans, Margherita Colangelo, Claudia Desogus, Constance Dobelmann, Adrien Giraud, Andrew Groves, Leigh Hancher, Behrang Kianzad, Christy Kollmar, Ioannis Lianos, Timo Minssen, Harald Mische, Giorgio Monti, Jotte Mulder, Okeoghene Odudu, Frantzeska Papadopoulou, Juliette Raffaitin, Wolf Sauter, Jan Truijens Martinez, Lourenço Ventura, Matthijs Versteegh
520			_aThis timely book discusses the application of the EU competition rules to pharmaceuticals, covering the prohibitions on anticompetitive agreements and abuse of dominance, and merger control. <br> The author team comprises academic experts and private practitioners who analyse recent case law at both EU (and UK) and Member State levels – in the context of current issues and future trends, including those related to COVID-19 – and examine the impact of competition law on the behaviour of the pharmaceutical industry. The book carefully considers the balance between competition and innovation, as well as between competition and regulation. It concludes that competition and regulation are not alternatives, but complementary, and that novel ways of taking into account risk and real innovation through competition assessments have been developed. <br> <b>TABLE OF CONTENTS:</b> <br> Foreword <br> PART I INTRODUCTION, LEGAL AND ECONOMIC CONTEXT <br> 1 Introduction. Marcel Canoy, Jotte Mulder and Wolf Sauter <br> 2 Excessive pricing doctrine in the pharmaceutical sector: the space for reform. Frederick M Abbott <br> 3 Evergreening exclusive rights in pharmaceutical products: the case of SPCs, paediatric extensions and orphan drugs. Frantzeska Papadopoulou <br> 4 The economics of patents and innovation in pharma. Marcel Canoy and Matthijs Versteegh <br> PART II THE COMPETITION CASES <br> SECTION IIA. PAY FOR DELAY AND PATENT STRATEGIES <br> 5 Settlement agreements acknowledging patent validity in the United Kingdom. Okeoghene Odudu <br> 6 Anticompetitive pharmaceutical patent settlements: the EU cases on pay-for-delay. Jotte Mulder and Wolf Sauter <br> SECTION IIB. EXCESSIVE PRICING <br> 7 The Aspen case of the Italian Competition Authority. Claudia Desogus <br> 8 Unfair pricing: policy considerations and recent experience in the pharmaceutical sector. Andrew Groves and Lourenço Ventura <br> 9 Temporary dominance and excessive pharmaceutical pricing – CD Pharma (Denmark). Behrang Kianzad <br> 10 Excessive pricing for pharmaceuticals in the Netherlands: the Leadiant case. Freek Bruggert and Clara Ceulemans <br> 11 The EU Aspen decision: the European Commission’s first excessive pricing decision in the pharmaceutical market. Harald Mische <br> SECTION IIC. DISPARAGEMENT AND MISLEADING INFORMATION <br> 12 Disparagement: the European Union and France. Adrien Giraud, Juliette Raffaitin and Constance Dobelmann <br> 13 The dissemination of misleading information in the pharmaceutical market: the Italian experience. Margherita Colangelo <br> SECTION IID. MERGERS AND PARALLEL TRADE <br> 14 EU merger control in the pharmaceutical sector: an overview. Jan Truijens Martinez <br> 15 Taking stock of the single market imperative in the Court’s case law on parallel trade in pharmaceuticals: are matters as settled as they seem? Jotte Mulder <br> PART III FUTURE DIRECTIONS <br> 16 Towards responsive enforcement of EU antitrust in pharmaceuticals. Wolf Sauter <br> 17 Excessive pricing in pharmaceuticals: perspectives from EU antitrust and regulation. Giorgio Monti and Leigh Hancher 18 Tackling grand challenges with competition law: lessons from the pandemic. Ioannis Lianos, Timo Minssen and Christy Kollmar <br> Index
650		4	_aCompetencia _9203
650		4	_aDerecho _9332
650		4	_aDerecho de la competencia _9356
650		4	_aSector farmacéutico _95908
650		4	_aFusiones y adquisiciones _9589
653		0	_aDefensa de la competencia
653		0	_aAntitrust
653		0	_aProductos farmacéuticos
653		0	_aPrecios excesivos
653		0	_aPatentes
653		0	_aInnovación tecnológica
653		0	_aPrácticas anticompetitivas
653		0	_aConcentración de empresas
653		0	_aControl de concentraciones
700	1		_aSauter, Wolf _eed. lit. _97641
700	1		_aCanoy, Marcel _eed. lit. _97642
700	1		_aMulder, Jotte _eed. lit. _97643
856	4	1	_zVer índice _uhttp://bibliotecacnmc.bage.es/cgi-bin/koha/opac-retrieve-file.pl?id=b1821a15d68c2ba285c5fab2e0b7aa62
942			_2udc _cMON